Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 17/20 | 0.71 |
| ▸ | AURKA | O14965 | 2/20 | 0.59 |
| ▸ | GRK2 | P25098 | 2/20 | 0.59 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.59 |
| ▸ | RPS6KA1 | Q15418 | 2/20 | 0.59 |
| ▸ | PRKCB | P05771 | 1/20 | 0.59 |
| ▸ | AKT1 | P31749 | 1/20 | 0.59 |
| ▸ | GRK5 | P34947 | 1/20 | 0.59 |
| ▸ | GRK6 | P43250 | 1/20 | 0.59 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.59 |
| ▸ | GRK7 | Q8WTQ7 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19759691 | 0.88 | ROCK2 (0.73) | ROCK2ROCK1 | |
| SCHEMBL19759688 | 0.87 | ROCK2 (0.65) | ROCK2GRK2 | |
| SCHEMBL19759687 | 0.87 | AURKA (0.58) | ROCK2AURKAGRK2ROCK1RPS6KA1 | |
| SCHEMBL19759774 | 0.87 | ROCK2 (0.73) | ROCK2 | |
| SCHEMBL19759689 | 0.86 | ROCK2 (0.67) | ROCK2 | |
| SCHEMBL17920319 | 0.85 | ROCK2 (0.65) | ROCK2 | |
| SCHEMBL19643514 | 0.83 | ROCK2 (0.83) | ROCK2AURKAGRK2ROCK1RPS6KA1 | |
| SCHEMBL19644001 | 0.83 | ROCK2 (1.00) | ROCK2AURKAGRK2ROCK1RPS6KA1 | |
| SCHEMBL19759738 | 0.82 | ROCK2 (0.62) | ROCK2GRK2 | |
| SCHEMBL19759681 | 0.82 | ROCK2 (0.55) | ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3242873-B1 | CYCLIC UREAS AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2020-07-22 | — | — | EP | disclosed |
| US-20180000788-A1 | CYCLIC UREAS AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2018-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180000788-A1 | CYCLIC UREAS AS INHIBITORS OF ROCK | MYLK, ROCK1, UACA | ROCK2 4/4885AURKA 585/4885GRK2 1776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.